Janux Therapeutics, Inc. (JANX)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| Revenue from contract with customer, including assessed tax | - | 439 | ||
| Research and development | 25,055 | 18,614 | ||
| General and administrative | 9,842 | 17,667 | ||
| Total operating expenses | 34,897 | 36,281 | ||
| Loss from operations | -34,897 | -35,842 | ||
| Interest income | 11,389 | 7,783 | ||
| Total other income | 11,389 | 7,783 | ||
| Net loss | -23,508 | -28,059 | ||
| Unrealized gain (loss) on available-for-sale securities, net | 1,593 | 9,447 | ||
| Comprehensive loss | -21,915 | -18,612 | ||
| Basic eps | -0.38 | -0.51 | ||
| Diluted eps | -0.38 | -0.51 | ||
| Basic average shares | 61,791,721 | 54,628,670 | ||
| Diluted average shares | 61,791,721 | 54,628,670 | ||